popular weight loss medications, one of the pharma companies behind the new treatments is making an interesting gambit: sponsoring studies into whether they can help treat other conditions.
"It builds this wall of evidence," explained Derek Asay, Lilly's senior vice president of government strategy and federal accounts. "It helps give that reason to believe there’s more than weight loss here." Known as glucagon-like peptide-1 agonists, drugs like Zepbound and Novo Nordisk's Ozempic and Wegovy are becoming known not just for inducing weight loss as they mimic the gut's feeling of fullness, but also for seemingly helping with other conditions ranging from
As more and more of these off-label uses begin cropping up in anecdotal evidence and studies, the companies that have made a killing off of them are hoping to get broader insurance coverage once regulatory agencies approve them for conditions outside of weight loss and diabetes.
I understand and agree that registration on or use of this site constitutes agreement to its User Agreement and Privacy Policy
Italia Ultime Notizie, Italia Notizie
Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.
Fonte: 10News - 🏆 732. / 50 Leggi di più »
Fonte: WGAL - 🏆 331. / 59 Leggi di più »
Fonte: PennLive - 🏆 463. / 53 Leggi di più »
Fonte: nypost - 🏆 91. / 67 Leggi di più »